基于脾-肠道菌群-原发性高血压探讨中医药调控作用  

Exploration on the regulatory effect of traditional Chinese medicine based on spleen-intestinal microflora-essential hypertension

作　　者：陈昭 张世亮[2] CHEN Zhao;ZHANG Shiliang(The First School of Clinical Medicine,Shandong University of Traditional Chinese Medicine,Jinan 250355,China;Section 4,Department of Cardiology,The Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250014,China)

机构地区：[1]山东中医药大学第一临床医学院,济南250355 [2]山东中医药大学附属医院心病四科,济南250014

出　　处：《中华中医药杂志》2024年第11期6012-6015,共4页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：国家科技重大专项(No.2017ZX09301003)。

摘　　要：文章从脾-肠道菌群角度出发,通过梳理肠道菌群在原发性高血压发病过程中的相似性、关联性,结合健脾方药可调控肠道菌群紊乱而发挥降压作用,故而推测从脾论治原发性高血压的潜在效应机制与靶向调节肠道菌群有关,探讨基于肠道菌群失调论治原发性高血压的现代科学意义,亦为相关降压药物研发提供新思路。From the perspective of spleen-intestinal microflora,this paper summarizes the similarity and correlation of intestinal microflora in the pathogenesis of essential hypertension,and combines the prescription of invigorating spleen to regulate intestinal microflora disorder and play a role in lowering blood pressure.Therefore,it is speculated that the potential effect mechanism of treating essential hypertension from spleen is related to targeted regulation of intestinal microflora,and the modern scientific significance of treating essential hypertension based on intestinal microflora disorder is discussed,which also provides new ideas for the research and development of related antihypertensive drugs.

关 键 词：原发性高血压 肠道菌群 从脾论治 脾虚痰浊 微生物 

分 类 号：R259[医药卫生—中西医结合]